Streetbeat News

TLSI

TriSalus Life Sciences, Inc.

https://trisaluslifesci.com

Industry

Medical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Open

4.30

Mkt cap

129M

Volume

31K

High

4.33

P/E Ratio

0.08

52-wk high

10.42

Low

4.16

Div yield

N/A

52-wk low

3.32

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Innovative Eyewear (LUCY), OneMedNet (ONMD), TransCode Therapeutics (RNAZ), Onconetix (ONCO), Aptorum Group (APM), and Immatics (IMTX). Major losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Exicure (XCUR), TriSalus Life Sciences (TLSI), and HOOKIPA Pharma (HOOK).

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 4:31 pm

U.S. stocks traded higher with the Nasdaq Composite gaining around 1%. Intuit shares fell 8% despite better-than-expected earnings due to weak guidance. Akanda Corp. shares surged 70% after a reverse stock split. Merus N.V. shares rose 37% following a positive abstract publication. Deckers Outdoor Corporation shares increased 13% on strong quarterly results. Verastem, Inc. shares dropped 61% after initiating a rolling NDA submission. TriSalus Life Sciences shares fell 26% following an exchange offer announcement. Genelux Corporation shares declined 45% after pricing a $27.5 million stock offering.

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 4:07 pm

JonesTrading analyst Justin Walsh initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 6:15 pm

TriSalus Life Sciences Inc. (NASDAQ:TLSI) has secured a debt financing deal with OrbiMed for up to $50 million to support growth initiatives for its TriNav Infusion System. The company received $25 million at closing, with an option for an additional $25 million based on revenue milestones. The funding aims to extend TriSalus's cash runway through 2025, support strategic expansion, and fuel growth without the immediate need for equity financing. The deal also includes a warrant for OrbiMed to purchase shares of TriSalus.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:37 pm

TriSalus Life Sciences (NASDAQ:TLSI) reported Q4 2023 earnings with a GAAP EPS of $(1.56), missing the $(0.69) estimate by 126.09%. However, their sales of $5.721M exceeded the $5.453M estimate by 4.91%, marking a 77.34% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:02 pm

Numerous companies are scheduled to report their quarterly earnings on April 1, 2024, with a mix of projected profits and losses across various sectors. Notable mentions include Mach Natural Resources with expected earnings of $0.92 per share, Sigma Lithium with $0.18 per share, and PVH Corp with a significant $3.53 per share. Conversely, companies like Enservco and Nano X Imaging are anticipating losses. This diverse earnings landscape provides a broad view of the financial health across different industries.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 9:13 am

TriSalus Life Sciences anticipates over 50% sales growth in 2024 and is seeking additional liquidity to support operations through the year. It expects to report $11.8 million in cash and equivalents by the end of 2023, with sufficient liquidity into Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:23 pm

TriSalus Life Sciences announced preliminary Q4 sales of around $5.7M, marking a 77% increase compared to 2022, with an estimated $5.453M. For 2023, the company forecasts revenues of about $18.5M, a 49% growth from 2022, and anticipates a gross margin of 90% for Q4 and 86% for the full year.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:21 pm

Trisalus Life Sciences has received approval from the World Health Organization and the American Medical Association's Adopted Name Council for 'nelitolimod' as the nonproprietary name for its drug SD-101.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:18 pm

TriSalus Life Sciences announced the publication of a real-world study on the effectiveness of its TriNav device for trans-arterial chemoembolization and trans-arterial radioembolization in patients with hepatocellular carcinoma and liver metastases. The study's findings could potentially enhance the company's reputation in the medical device sector and impact its market position.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.